In this episode titled "The Future of Vitiligo Care: Patient Selection, Treatment Access, and the Road Ahead," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD offer a forward-looking discussion on incorporating systemic JAK inhibitors into clinical practice, individualizing patient selection, and ensuring equitable access to emerging therapies.
In this episode titled "Systemic JAK Inhibitors for Vitiligo: Emerging Clinical Trial Data and Safety Considerations," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD review the emerging pipeline of oral JAK inhibitors for vitiligo and discuss the safety considerations relevant to this therapeutic class.
In this episode titled "JAK Inhibitors in Vitiligo: Mechanism, Efficacy, and Durability," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD explore the scientific rationale for JAK inhibitor therapy and review clinical evidence for the first FDA-approved topical agent in this class.
In this episode titled "Setting Expectations: Treatment Timelines, Adherence, and Monitoring in Vitiligo," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD discuss realistic repigmentation timelines, adherence strategies, and how to keep patients motivated throughout the long treatment journey.
In this episode titled "Shared Decision-Making and the Vitiligo Treatment Landscape," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD discuss the importance of individualized, goal-directed decision-making in vitiligo treatment and provide an overview of available therapeutic options.
In this episode titled "Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD address the clinical distinction between active and stable vitiligo, as well as the significant psychological impact of the disease.
In this episode titled "Vitiligo Pathogenesis: How the JAK-STAT Pathway Drives Melanocyte Destruction," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD explore the immunological underpinnings of vitiligo and how this understanding has revolutionized treatment thinking.
The panel turns to taking a thorough patient history, performing a complete physical exam, and ordering appropriate laboratory workup when evaluating a patient with vitiligo.
The panel reframe vitiligo as a chronic autoimmune disease affecting 1–2% of the global population, emphasizing its clinical presentations, associated comorbidities, and significant psychosocial impact on patients across all skin types.
